Home Funding  SoundHealth Secures $7 Million Seed Funding and launches SONU

[Funding News] SoundHealth Secures $7 Million Seed Funding and launches SONU

0
SoundHealth, a medical technology company harnessing the power of artificial intelligence and medical science to improve patient outcomes, introduced SONU and received $7 million of seed-round funding. SONU is the world’s first FDA De Novo authorized, AI-enabled, wearable medical device for the treatment of moderate to severe nasal congestion due to allergic and non-allergic rhinitis for at-home use by individuals 22 years of age and older.
SoundHealth, a medical technology company harnessing the power of artificial intelligence and medical science to improve patient outcomes, introduced SONU and received $7 million of seed-round funding. SONU is the world’s first FDA De Novo authorized, AI-enabled, wearable medical device for the treatment of moderate to severe nasal congestion due to allergic and non-allergic rhinitis for at-home use by individuals 22 years of age and older.
SoundHealth, a medical technology company harnessing the power of artificial intelligence and medical science to improve patient outcomes, introduced SONU and received $7 million of seed-round funding. SONU is the world’s first FDA De Novo authorized, AI-enabled, wearable medical device for the treatment of moderate to severe nasal congestion due to allergic and non-allergic rhinitis for at-home use by individuals 22 years of age and older.

SoundHealth, a medical technology company harnessing the power of artificial intelligence and medical science to improve patient outcomes, introduced SONU and received $7 million of seed-round funding. SONU is the world’s first FDA De Novo authorized, AI-enabled, wearable medical device for the treatment of moderate to severe nasal congestion due to allergic and non-allergic rhinitis for at-home use by individuals 22 years of age and older.

Read also – [Funding News] Clarapath Secures $36 Million B-1 Funding

SONU provides a new non-pharmaceutical treatment option for patients and clinicians. The United States Food and Drug Administration (FDA) issued a De Novo classification for the SONU product, which includes the SONU device and the SONU app.

Read also – [Funding News] Star Catcher Secures $12.25 Million Seed Funding

SoundHealth will use the funds to enhance the commercialization and marketing of SONU and to seek regulatory authorization for additional indications for pediatric use and insomnia. Moai Capital and J4 Ventures led the round with additional funding from TeleSoft Partners, Tau Ventures, TechU Ventures and Rhythm Venture Capital. Peter Moran, an early-stage investor in digital health and wellness companies, a former long-time managing partner at DCM Ventures, and a seed investor in SoundHealth, will join the SoundHealth board of directors. The investor syndicate has a long track record of successful investments in groundbreaking solutions from both enterprise and health tech startups.

“We are delighted to announce the close of our seed-round investment — the proceeds of which will be used for product launch and advancing our pipeline of indications for the SONU device. Our groundbreaking technology provides the first FDA authorized, non-pharmaceutical medical device treatment option for nasal congestion due to allergic and non-allergic rhinitis. SoundHealth’s mission is to provide personalized, intelligent wearables to help people breathe and sleep better!” said Dr. Paramesh Gopi, founder and CEO, SoundHealth.

“We were especially struck by how quick and easy SONU can bring relief to allergies, without using a drug. Future applications could include helping with sleep and stress,” said Amit Garg, managing partner of Tau Ventures.

SONU is an AI-enabled patented drug-free medical device that uses acoustic vibrational energy to provide personalized relief for nasal congestion. Acoustic vibration associated with humming has been shown to decrease symptoms of nasal congestion, possibly through modulation of autonomic inputs to the nasal mucosa or through nitric oxide activity, which may in turn exert a decongestant and anti-inflammatory effect on the nasal passages.

SONU is easy, convenient and pleasant to use for patients. Using SoundHealth’s proprietary AI technology, the SONU app scans their face using a smartphone, creates a digital map of their sinuses and calculates their optimal resonant frequencies. Following the initial one-time scan, the patient simply places the SONU band around their head, turns it on and the SONU band delivers frequencies tailored to the patient based on the app’s calculations. Symptom relief begins in minutes. Patients do not need to change their activities while using SONU. They can enjoy SONU anytime at home just for 15 minutes twice a day, for example, while online, brushing their teeth, drinking their morning coffee, exercising or watching TV.

About SoundHealth

SoundHealth is a medical technology company harnessing the power of artificial intelligence and medical science to improve respiratory health. The SoundHealth team consists of experienced medical professionals, data scientists and engineers who are passionate about improving healthcare. SoundHealth investors include Moai Capital, J4 Ventures, TeleSoft Partners, Tau Ventures, TechU Ventures, Rhythm Venture Capital and Peter Moran.

Exit mobile version